Biobytes

INVESTOR RELATIONS & NOTICE

Through transparent communication,we share the value of innovation

Follow Biobytes' growth as we work toward healthier aging,
with transparent access to key business updates and disclosures for shareholders and partners.

STAGE

Series A

MILESTONE

  • Phase 1 entry for our sarcopenia drug
  • Approval of our AI SW medical device for sarcopenia risk
  • KRW 3B+ annual supplement sales and global expansion

PIPELINE

Preclinical studies for sarcopenia drug BB-SAR-001(Joint R&D and technology transfer for BB-SAR-002–005)

IR Data Room

The latest company materials for investors and partners.

2026.10

(KOR)BioBytes Corporate IR

The latest IR deck presenting BioBytes' vision, business model, drug pipeline progress, and future financing and IPO roadmap.

KOR Download
2026.10

BioBytes Corporate IR

The latest IR deck presenting BioBytes' vision, business model, drug pipeline progress, and future financing and IPO roadmap.

ENG Download

Notices & Announcements

Official company notices issued under the Commercial Act and our articles of incorporation.

No notices published.

0 notices in total, page 1 of 1